ELISA

…Serum Amyloid A (SAA) Concentration SAA concentrations were measured using a solid-phase sandwich ELISA kit (PHASE™ Serum Amyloid A Assay, Tridelta Development Ltd., Maynooth, Ireland) following the manufacturer’s instructions. Absorbance…

concentration (ng/mL) was analysed using Animals 2020, 10, 1255 5 of 14 a competitive ELISA assay (Salivary Cortisol ELISA SLV-2930, DRG Diagnostics, Marburg, Germany). The intra- and inter-assay CV…

…PigMAP concentration in serum was measured by sand- No other variable or interaction affected productive per- wich ELISA with two monoclonal antibodies, using a formance or pre-weaning mortality. commercial kit (pigMAP…

…PigMAP concentration in serum was measured by sand- No other variable or interaction affected productive per- wich ELISA with two monoclonal antibodies, using a formance or pre-weaning mortality. commercial kit (pigMAP…

…PigMAP concentration in serum was measured by sand- No other variable or interaction affected productive per- wich ELISA with two monoclonal antibodies, using a formance or pre-weaning mortality. commercial kit (pigMAP…

…PigMAP concentration in serum was measured by sand- No other variable or interaction affected productive per- wich ELISA with two monoclonal antibodies, using a formance or pre-weaning mortality. commercial kit (pigMAP…

…PGE2 concentrations were measured using a commercial enzyme-linked immunosorbent assay (ELISA; catalog No. 514531; Cayman Chemical) following the method described by Giorgi et al., (2011). Briefly, serum samples were purified by…

…PGE2 concentrations were measured using a commercial enzyme-linked immunosorbent assay (ELISA; catalog No. 514531; Cayman Chemical) following the method described by Giorgi et al., (2011). Briefly, serum samples were purified by…

…Concentra-tions of SC and SAA were determined using ELISA assays (Salivary Cortisol ELISA SLV-2930, DRG Diagnostics, Marburg, Germany; PHASE TM Serum Amyloid A Assay, Tridelta Development Ltd., Maynooth, Ireland). Statistical…

lable, pre-treatment data were included as a co-variate. Baseline data were defined as the latest measurement of a given variable before treatment was administered. The statistical model included treatment, sex (except for parameters only measured in one sex), and treatment-by-sex interactions as fixed effects, while the repeated measures ANOVA model included treatment, sex and time (and their 2-way and 3-way interac- tions) as fixed effects. Data were compared either within or across sex depending on observed interactions. Models were selected using backwards elimination where 3-way and 2-way interaction terms with the highest p-Value were sequentially dropped from the model. The process was performed hierarchically starting with the 3-way interaction terms using a threshold p-Value of 0.1, as required by regulatory guidelines. Model selection was stopped when any of the following occurred: (i) all interaction terms at the highest level had a p-Value < 0.1; (ii) no interaction terms remained in the model. The statistical model was therefore: Parameter = Baseline_variables + Treatment + Sex + Time + Treatment:Sex + Treat- ment:Time + Sex:Time + Treatment:Sex:Time + Residual_Error Least squares means were compared at a significance level of p < 0.1 in the first instance apart from treatment by sex by time point, which was compared at p < 0.05 in the first instance. For the repeated measures models, most residual error patterns were selected based on a comparison of Akaike Information Criteria (AIC) output for models containing an unstructured (UN), autoregressive (AR; 1), variance components (VC) and independent residual error pattern (with the lowest AIC preferred among the possible covariance matrices). The denominator degrees of freedom in the covariance pattern